Last reviewed · How we verify
NCT00434239
A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia.
EARLY_PHASE1 trial testing Lenalidomide + Ancestim in Myelodysplasia in 25 participants. Status unknown.
1 May 2011
Quick facts
| Lead sponsor | Peter MacCallum Cancer Centre, Australia |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 February 2007 |
| Primary completion | 1 May 2011 |
| Estimated completion | 1 May 2014 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Lenalidomide + Ancestim — full drug profile →
Conditions studied
- Myelodysplasia — all drugs for Myelodysplasia →
Sponsor
Peter MacCallum Cancer Centre, Australia — full company profile →
Who can join
18 and older, any sex, with Myelodysplasia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Toxicity as defined by NCI-CTCv3.0
Time frame: 3 years
Sponsor's own description
This study is mainly assessing the safety of Revlimid in combination with Ancestim (recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical responses will also be assessed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00434239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myelodysplasia
Currently open trials in the same condition.
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT05735717 — MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies · Phase 2 · recruiting
- NCT04202835 — ATG Plus PTCy vs ATG for CGVHD Prophylaxis · Phase 2 · active not recruiting
- NCT03674411 — Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · Phase 2 · active not recruiting
- NCT03314974 — Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · Phase 2 · recruiting
Other Peter MacCallum Cancer Centre, Australia trials
Trials by the same sponsor.
- NCT07217938 — Novel Treatment of Radiation Associated Dysphagia With Statins · Phase 2 · recruiting
- NCT07051525 — Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapi · NA · recruiting
- NCT07263815 — EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET · NA · active not recruiting
- NCT07090369 — Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Cast · Phase 1 · not yet recruiting
- NCT07139782 — Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Canc · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00434239 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peter MacCallum Cancer Centre, Australia
- Last refreshed: 8 January 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00434239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing